Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Shares Up 9% – Still a Buy?

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD)’s stock price traded up 9% during trading on Tuesday . The company traded as high as $0.4129 and last traded at $0.3870. 156,252 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 294,953 shares. The stock had previously closed at $0.3552.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Friday, May 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Hong Kong Pharma Digital Technology has a consensus rating of “Sell”.

Hong Kong Pharma Digital Technology Stock Up 9.0%

The firm’s 50 day simple moving average is $0.46 and its 200-day simple moving average is $0.62.

Institutional Investors Weigh In On Hong Kong Pharma Digital Technology

An institutional investor recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. bought a new stake in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology at the end of the most recent reporting period.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.